Provided by Tiger Trade Technology Pte. Ltd.

Beam Therapeutics, Inc.

25.18
-1.6550-6.17%
Pre-market: 25.350.1750+0.70%08:45 EDT
Volume:2.85M
Turnover:72.77M
Market Cap:2.60B
PE:-30.06
High:26.70
Open:26.70
Low:25.11
Close:26.83
52wk High:38.26
52wk Low:19.57
Shares:103.29M
Float Shares:91.60M
Volume Ratio:1.32
T/O Rate:3.11%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8376
EPS(LYR):-0.8100
ROE:-8.18%
ROA:-17.01%
PB:2.44
PE(LYR):-31.08

Loading ...

Clear Street sees buying opportunity for Beam Therapeutics after study update

TIPRANKS
·
Mar 26

Beam Therapeutics: BEAM-302’s Differentiated AATD Profile and Accelerated Path Support Buy Rating and $80 Target

TIPRANKS
·
Mar 25

A Look At Beam Therapeutics (BEAM) Valuation After Positive BEAM 302 Data And Accelerated Approval Plans

Simply Wall St.
·
Mar 25

BUZZ-U.S. STOCKS ON THE MOVE-Arm, Destiny Tech100, Terns Pharma

Reuters
·
Mar 25

BUZZ-Beam Therapeutics rises after gene-editing drug shows promise in rare lung and liver disease

Reuters
·
Mar 25

Beam Therapeutics Shares up 14% Premarket After Co's Gene‑Editing Drug Showed Promising Results in Trial for Rare Lung and Liver Disease

THOMSON REUTERS
·
Mar 25

Beam Therapeutics selects 60 mg BEAM-302 for pivotal development; Phase 1/2 trial mean steady-state total AAT climbs to 16.1 µM at 60 mg

Reuters
·
Mar 25

Beam Therapeutics Inc: Global Pivotal Cohort Expected to Initiate in Second Half of 2026

THOMSON REUTERS
·
Mar 25

Beam Therapeutics: Corrected M-Aat Comprised 94% of Total Aat With a Concomitant 84% Reduction in Mutant Z-Aat Following Beam-302 60 Mg Treatment

THOMSON REUTERS
·
Mar 25

Beam Therapeutics Inc: 60 Mg Selected as Optimal Biological Dose, Supported by Strong Safety and Efficacy Profile Across Single-Dose Cohorts

THOMSON REUTERS
·
Mar 25

Hitachi Cooling & Heating Supports Hong Kong's Net-Zero Transition with BEAM Plus-Aligned VRF Solutions

prnewswire
·
Mar 23

Analysts Are Bullish on These Healthcare Stocks: Beam Therapeutics (BEAM), Pelthos Therapeutics (PTHS)

TIPRANKS
·
Mar 16